162 related articles for article (PubMed ID: 28637022)
1. CDKN2A methylation in esophageal cancer: a meta-analysis.
Zhou C; Li J; Li Q
Oncotarget; 2017 Jul; 8(30):50071-50083. PubMed ID: 28637022
[TBL] [Abstract][Full Text] [Related]
2. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
[TBL] [Abstract][Full Text] [Related]
3. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
[TBL] [Abstract][Full Text] [Related]
4. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Abou-Zeid AA; Azzam AZ; Kamel NA
Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
[TBL] [Abstract][Full Text] [Related]
5. The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis.
Li J; Zhou C; Zhou H; Bao T; Gao T; Jiang X; Ye M
Ther Clin Risk Manag; 2016; 12():1249-60. PubMed ID: 27574435
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of hypermethylation of p16 gene in esophageal cancer.
Xu R; Wang F; Wu L; Wang J; Lu C
Cancer Biomark; 2013; 13(4):215-26. PubMed ID: 24240582
[TBL] [Abstract][Full Text] [Related]
7. Associations of risk factors obesity and occupational airborne exposures with CDKN2A/p16 aberrant DNA methylation in esophageal cancer patients.
Mohammad Ganji S; Miotto E; Callegari E; Sayehmiri K; Fereidooni F; Yazdanbod M; Rastgar-Jazii F; Negrini M
Dis Esophagus; 2010 Sep; 23(7):597-602. PubMed ID: 20459442
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
Zhou Y; Wang XB; Qiu XP; Shuai Zhang ; Wang C; Zheng F
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):529-541. PubMed ID: 30143452
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.
Tang B; Li Y; Qi G; Yuan S; Wang Z; Yu S; Li B; He S
Sci Rep; 2015 Sep; 5():13563. PubMed ID: 26338139
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex.
Alves MK; Faria MH; Neves Filho EH; Ferrasi AC; Pardini MI; de Moraes Filho MO; Rabenhorst SH
Int J Surg; 2013; 11(7):549-53. PubMed ID: 23721661
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma.
Ito S; Ohga T; Saeki H; Watanabe M; Kakeji Y; Morita M; Yamada T; Maehara Y
Anticancer Res; 2007; 27(5A):3345-53. PubMed ID: 17970080
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma.
Su L; Wang H; Miao J; Liang Y
Sci Rep; 2015 Aug; 5():13238. PubMed ID: 26283007
[TBL] [Abstract][Full Text] [Related]
13. Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer.
Lamy A; Sesboüé R; Bourguignon J; Dautréaux B; Métayer J; Frébourg T; Thiberville L
Int J Cancer; 2002 Jul; 100(2):189-93. PubMed ID: 12115568
[TBL] [Abstract][Full Text] [Related]
14. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
[TBL] [Abstract][Full Text] [Related]
15. Role of
Li J; Ye D; Wang L; Peng Y; Li Q; Deng H; Zhou C
Onco Targets Ther; 2018; 11():651-663. PubMed ID: 29440913
[TBL] [Abstract][Full Text] [Related]
16. The relationship between P16
Poosari A; Nutravong T; Namwat W; Wasenang W; Sa-Ngiamwibool P; Ungareewittaya P
Sci Rep; 2022 Jun; 12(1):10337. PubMed ID: 35725923
[TBL] [Abstract][Full Text] [Related]
17. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma.
Hibi K; Taguchi M; Nakayama H; Takase T; Kasai Y; Ito K; Akiyama S; Nakao A
Clin Cancer Res; 2001 Oct; 7(10):3135-8. PubMed ID: 11595706
[TBL] [Abstract][Full Text] [Related]
18. [Methylation of p16 and hMLH1 genes in esophageal squamous cell carcinoma and reflux esophagitis].
Wang F; Xie XJ; Piao YS; Liu B; Wang LD
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):537-41. PubMed ID: 22169643
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
Cao Z; Wei L; Zhu W; Yao X
Medicine (Baltimore); 2018 Mar; 97(12):e0182. PubMed ID: 29561434
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
